TransCode Therapeutics reports promising preclinical glioblastoma results

Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.
Le Lézard

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

TransCode Therapeutics, Inc. , a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the publication of ...

TransCode Therapeutics stock soars after promising glioblastoma study

Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 18% on Tuesday after the company published preclinical data showing its lead candidate TTX-MC138 demonstrated therapeutic potential ...

Biomednewsbreaks - Transcode Therapeutics, Inc. (NASDAQ: RNAZ) Publishes Preclinical Data Supporting TTX-MC138 For Glioblastoma

Publishes Preclinical Data Supporting TTX-MC138 For Glioblastoma. TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead ...
Hackaday

Low-Cost, Portable Streaming Server

Thanks to the Raspberry Pi, we have easy access to extremely inexpensive machines running Linux that have all kinds of GPIO ...
Investing

TransCode Therapeutics appoints Jack E. Stover to board of directors

BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company focused on immuno-oncology and RNA treatments for advanced cancer, announced Monday the appointment of Jack E. Stover to ...
Seeking Alpha

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique ...

TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...